Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin microneedle array - SkinJect

Next Previous
Drug Profile

Doxorubicin microneedle array - SkinJect

Alternative Names: D-MNA; Doxorubicin-containing MNA - SkinJect; SkinJect™

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkinJect
  • Class Alcohols; Amines; Anisoles; Anthracyclines; Antineoplastics; Benzoquinones; Catechols; Cyclic ethers; Cyclohexanols; Cytostatic antibiotics; Doxorubicins; Ketones; Naphthacenes; Pyrans; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Basal cell cancer

Most Recent Events

  • 17 Apr 2026 Medicus Pharma submits orphan drug designation application to USFDA for Basal cell cancer
  • 30 Mar 2026 Updated efficacy data from the phase-II SKNJCT-003 trial in Basal cell cancer released by Medicus Pharma
  • 16 Mar 2026 Efficacy data from a phase II trial in Basal cell cancer released by Medicus Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top